Entera Bio (ENTX) awards 180,000 options to Chief of R&D
Rhea-AI Filing Summary
Entera Bio Ltd. granted its Chief of R&D, Gregory Burshtein, 180,000 stock options to purchase ordinary shares at an exercise price of $1.37 per share. The options expire on May 7, 2036 and vest over three years starting May 7, 2026, with full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Burshtein Gregory
Role
Chief of R&D
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 180,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 180,000 shares (Direct)
Footnotes (1)
- F1. Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).
Key Figures
Option grant size: 180,000 shares
Exercise price: $1.3700 per share
Expiration date: May 7, 2036
+2 more
5 metrics
Option grant size
180,000 shares
Stock options to purchase ordinary shares granted to Chief of R&D
Exercise price
$1.3700 per share
Conversion or exercise price of granted stock options
Expiration date
May 7, 2036
Expiry of stock options granted to Chief of R&D
Vesting period
3 years
Options vest over three years beginning May 7, 2026
Initial vesting date
May 7, 2027
One third of options vest on this date
Key Terms
Registration Statement on Form S-8, Change in Control, 2018 Equity Incentive Plan, vest over a three year period
4 terms
Registration Statement on Form S-8 regulatory
"subject to the filing by the Company of a Registration Statement on Form S-8"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
Change in Control financial
"subject to full acceleration upon a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2018 Equity Incentive Plan financial
"as defined in the Company's 2018 Equity Incentive Plan"
vest over a three year period financial
"The options vest over a three year period which began on May 7, 2026"
FAQ
What insider transaction did Entera Bio (ENTX) report for Gregory Burshtein?
Entera Bio granted Chief of R&D Gregory Burshtein 180,000 stock options to purchase ordinary shares at an exercise price of $1.37 per share, expiring on May 7, 2036, as part of its equity compensation program.
How many stock options were granted to Entera Bio (ENTX) Chief of R&D and at what price?
Gregory Burshtein received 180,000 stock options with an exercise price of $1.37 per share. Each option represents the right to buy one ordinary share of Entera Bio, subject to the vesting schedule and other plan terms.
What is the vesting schedule for the Entera Bio (ENTX) options granted to the Chief of R&D?
The options vest over a three-year period starting May 7, 2026. One third vests on May 7, 2027, and the remaining two thirds vest ratably on a quarterly basis over the following two years, subject to continued service conditions.
When do Gregory Burshtein’s Entera Bio (ENTX) stock options expire?
The granted stock options expire on May 7, 2036. After this expiration date, any unexercised options will lapse, meaning they can no longer be used to purchase Entera Bio ordinary shares under this grant.
Do the Entera Bio (ENTX) options accelerate upon a Change in Control?
Yes. The options are subject to full acceleration upon a Change in Control, as defined in Entera Bio’s 2018 Equity Incentive Plan. This means all unvested options would become fully vested if such a corporate event occurs.
Were the Entera Bio (ENTX) options granted under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox was not selected, so this 180,000-option grant to the Chief of R&D was not reported as being made pursuant to a pre-arranged Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
